Clinical Trial

RCT for the Chinese Medicine in Treating Hypercholesterolemia

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a randomized, double-blind, placebo-controlled clinical trial. Eligible subjects will randomized into a treatment group or placebo group. They will receive either Chinese medicine granules or placebo granules for 8 weeks followed by a 4-week observation period. The primary outcome would be the percent change in Low-density lipoprotein cholesterol levels (LDL-C) after treatment.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-12 -> 2029-12 2026-07-31
minor Completion pushed: 2027-04 -> 2030-04 2026-07-31
Trial Details
NCT Number NCT06700408
Lead Sponsor Chinese University of Hong Kong
Conditions Hypercholesterolemia
Enrollment 70 participants
Start Date 2027-01
Primary Completion 2029-12 (estimated)
Study Completion 2030-04 (estimated)
Updated on ClinicalTrials.gov 2026-07-30